Drug Type Probiotics |
Synonyms |
Target |
Mechanism LEKTI replacements(Serine protease inhibitor Kazal-type 5 replacements) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ResVita Bio, Inc.Startup |
Active Organization ResVita Bio, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationRare Pediatric Disease (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Netherton Syndrome | Preclinical | US | ResVita Bio, Inc.Startup | 09 Jun 2022 |